Gyre Therapeutics (GYRE) Accumulated Depreciation & Amortization (2011 - 2026)

Gyre Therapeutics (GYRE) has 13 years of Accumulated Depreciation & Amortization data on file, last reported at $8.2 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization rose 34.38% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 34.38% YoY) and the FY2025 annual result came in at $7.6 million, up 35.31% from the prior year.
• Accumulated Depreciation & Amortization climbed to $8.2 million in Q1 2026 per GYRE's latest filing, from $7.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $8.2 million in Q1 2026 and bottomed at $4.0 million in Q4 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $5.6 million (2024), against an average of $5.8 million.
• The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization rose 6.68%; it then soared 35.31% in 2025.
• Tracing GYRE's Accumulated Depreciation & Amortization over 5 years: stood at $4.0 million in 2022, then climbed by 6.68% to $4.3 million in 2023, then surged by 31.28% to $5.6 million in 2024, then soared by 35.31% to $7.6 million in 2025, then rose by 7.79% to $8.2 million in 2026.
• Per Business Quant, the three latest GYRE Accumulated Depreciation & Amortization figures stand at $8.2 million (Q1 2026), $7.6 million (Q4 2025), and $6.9 million (Q3 2025).

Peer Comparison